Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class fatty acid synthase (FASN) inhibitors at the upcoming AASLD meeting. Poster #1972 “Pharmacologic inhibition of FASN reverses diet-induced steatohepatitis in mice and inhibits lipogenesis in humans” presents data from a Phase 1 clinical-pharmacology study conducted in collaboration with leading experts in the field, Drs. Elizabeth Parks and Camila Manrique at the University of Missouri, Columbia School of Medicine. This study shows that 3-V Biosciences’ lead drug, TVB-2640, directly inhibits hepatic lipogenesis, a driver of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), in healthy males who have characteristics of metabolic syndrome (i.e. BMI >26). A second poster #1994 “Fatty acid synthase inhibitor TVB-3664 reduces collagen accumulation in bleomycin-induced murine skin fibrosis and reverses multiple components of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone” was recognized as a Presidential Poster of Distinction. These studies describe the therapeutic potential of FASN inhibitors in mouse models of NASH and their ability to decrease expression of genes associated with fibrosis in human liver stellate cells.
Presentation date: Monday October 23, 2017
Presentation time: 12:30PM – 2:00PM local time
About 3-V Biosciences
3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in metabolic and oncologic diseases based on expertise in lipid biology. The company’s lead product candidate, TVB-2640, is a first-in-class inhibitor of FASN currently being evaluated in a Phase 1 clinical trial. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. The company is located in Menlo Park, California.
Corporate Development & Finance